MeiraGTx Holdings (MGTX) said Tuesday it has seen encouraging data from a phase 1/2 clinical study of botaretigene sparoparvovec to treat patients with...
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
MeiraGTx Holdings (MGTX) has an average rating of buy and price targets ranging from $18 to $55, according to analysts polled by Capital IQ. (MT Newswires...
| Address | 430 East 29th Street New York, New York 10016 |
| Phone | +1.646.860.7985 |
| Number of Employees | 68 |
| Recent SEC Filing | 06/27/2022 8-K |
| President, Chief Executive Officer & Director | Alexandria Forbes |
| Chief Operating & Financial Officer | Richard Giroux |
| Chief Medical Officer | Robert K. Zeldin |
| Chief Development Officer | Stuart Naylor |
| Price Open | $7.69 |
| Previous Close | $7.57 |
| 52 Week Range | $6.59 - 24.89 |
| Market Capitalization | $338.5 M |
| Shares Outstanding | 44.7 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 08/10/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$1.96 |
| Beta vs. S&P 500 | N/A |
| Revenue | $0.00 |
| Net Profit Margin | -224.55% |
| Return on Equity | -47.00% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
